Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-Valvular Atrial Fibrillation
Conditions
Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure
Trial Timeline
Mar 23, 2017 → Dec 31, 2019
NCT ID
NCT03088072About Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin
Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin is a approved stage product being developed by Daiichi Sankyo for Non-Valvular Atrial Fibrillation. The current trial status is unknown. This product is registered under clinical trial identifier NCT03088072. Target conditions include Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure.
What happened to similar drugs?
1 of 2 similar drugs in Non-Valvular Atrial Fibrillation were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03088072 | Approved | UNKNOWN |
Competing Products
17 competing products in Non-Valvular Atrial Fibrillation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edoxaban | Daiichi Sankyo | Pre-clinical | 26 |
| DU-176b 15mg + DU-176b 30mg + DU-176b 60mg | Daiichi Sankyo | Phase 3 | 40 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 26 |
| AZD0837 + Aspirin | AstraZeneca | Phase 2 | 35 |
| Apixaban + Warfarin | Pfizer | Pre-clinical | 26 |
| Warfarin + Apixaban | Pfizer | Pre-clinical | 26 |
| Apixaban | Bristol Myers Squibb | Approved | 43 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 18 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban(Xarelto,BAY 59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto,Bay 59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto, BAY59-7939) + Warfarin | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto, BAY-597939) + VKAs | Bayer | Pre-clinical | 23 |
| Non-VKA Oral Anticoagulants (NOAC) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto_ BAY59-7939) | Bayer | Pre-clinical | 23 |
| Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan) | Bayer | Pre-clinical | 15 |